Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

The exercise period for subscription of shares through exercise of warrants of series TO5 begins today

NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, JAPAN, NEW ZEALAND, RUSSIA, SOUTH AFRICA, SOUTH KOREA, CANADA, OR IN ANY OTHER JURISDICTION WHERE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE FURTHER ACTIONS BEYOND THOSE REQUIRED BY SWEDISH LAW. Today, 6 November 2024, the exercise period for warrants of series TO5 (“TO5”) in PEPTONIC medical AB ("Peptonic" or “the Company”) begins. The exercise period runs from and including November 6, 2024, until and including November 20, 2024. Each TO5 entitles

In-depth analysis showing robust Diamyd[®] treatment effects across clinical trials to be shared at the 2024 IDS Diabetes Congress

Diamyd Medical will present new analysis results on November 7 at the 20th Immunology of Diabetes Society (IDS) Congress in Bruges, Belgium. The analysis will be presented at a Satellite Symposium organized by Abbott. The results support the robustness of the treatment effects and underscore the potential for precision medicine to slow and delay disease progression in Type 1 Diabetes.”These analyses clarify the robustness of our previous treatment results across trials in our genetically defined responder patient group, and further characterize the effect of Diamyd[®] on glycemic control”,

PHI's new CEO to BioStock: "I am excited to lead us forward with new energy"

Anders Månsson was recently appointed CEO of Phase Holographic Imaging. With extensive leadership experience in the international life sciences sector, he aims to expand PHI’s global reach and position the company as a leader in non-invasive cell quality control technologies. We spoke with him about his vision for the future.Read the full interview with Anders Månsson at biostock.se: https://www.biostock.se/en/2024/11/phis-new-ceo-i-am-excited-to-lead-us-forward-with-new-energy/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

Announcement of a Change in Shareholding According to Chapter 9, Section 10 of the Finnish Securities Market Act

Sitowise Group Plc Stock Exchange Release 6 November 2024 at 9.45 a.m. (EET) Sitowise Group Plc (the "Company") has on 5 November 2024 received a notification in accordance with the Chapter 9, Section 10 of the Finnish Securities Market Act from Morgan Stanley, according to which Morgan Stanley & Co International Plc's holding of the shares and votes of the Company has increased above 5.00 percent on 4 November 2024. According to the notification, Morgan Stanley holds indirectly a total of 46,560 shares corresponding to 0.13 percent of the Company’s shares and votes, and a total of 2,

Renowned international expert in medicine Dr. Charles Alessi joins Nightingale Health UK as Chief Medical Officer

Nightingale Health Plc Press release 6 November 2024 at 09:45 a.m. (EET)   Nightingale Health, a pioneer in disease risk detection and preventative health has appointed internationally recognised expert in medicine Dr. Charles Alessi as Chief Medical Officer of Nightingale Health UK.   Dr. Charles Alessi is a physician with more than 35 years of experience in all aspects of policy and clinical practice in the United Kingdom, Northern Ireland and globally. Alessi’s experience includes key positions in some of the world leading organisations in the industry, such as acting

NYAB AB’s Interim Report January-September 2024: Doubled order backlog and strong profit improvement

· Solid revenue growth and strong project execution · Improved operating margins and net profit · Favorable market conditions resulting in a record-high order backlog July-September in brief · Revenue amounted to EUR 93.6 (88.1) million, representing a change of 6.2%. In constant currencies, revenue growth was 4.2%. · Operating profit (EBIT) improved 35.4% and was EUR 8.9 (6.6) million, amounting to 9.5% (7.5%) of revenue. · Free cash flow was EUR -8.3 (-3.8) million. · Net debt/EBITDA was 0.06 (0.30). · Order backlog improved 108.4% and amounted to EUR 381.9 (183.

Aixia continues to grow with a new client in property management and aims for future AI business

Mölndal                                                                                      2024-11-06 Aixia has signed a significant agreement with a new customer in property management. This collaboration marks a strategic step forward for Aixia, as the company sees great opportunities to introduce AI solutions in this industry In the new assignment, Aixia's expertise will take overall responsibility for the customer's operating environment, drive important improvement projects and ensure that the IT architecture is optimized for the demands and needs of the future. The

BioStock: Cereno Scientific’s CEO on novel therapies for rare diseases

BioStock met with Cereno Scientifics CEO Sten R. Sörensen at BioEurope. Cereno Scientific is developing novel therapies for rare diseases, with a mission to bring innovative treatments to enhance and extend the lives of patients with high unmet medical needs. In this interview, Sten shares insights on the company’s current projects, their objectives at BioEurope, and the future ahead.Watch the interview with Cereno Scientific at biostock.se:https://www.biostock.se/en/2024/11/cereno-scientifics-ceo-on-novel-therapies-for-rare-diseases/This is a press release from BioStock - Connecting

Invitation to presentation of BioArctic’s third quarter report for July - September 2024 on November 14 at 9.30 a.m. CET

Stockholm, Sweden, November 6, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will publish the company’s third quarter report for July – September 2024 on Thursday, November 14, 2024, at 08:00 a.m. CET.In conjunction to the report, BioArctic invites investors, analysts, and media to an audiocast with teleconference (in English) on November 14, at 09:30 CET, where Gunilla Osswald, CEO, and Anders Martin-Löf, CFO, will present and comment on the third quarter report, followed by a Q&A-session. If you wish to participate via webcast, please use the link below. Via the webcast you

Compressor distributor in Türkiye has become part of Atlas Copco Group

Nacka, Sweden, November 6, 2024: SCS Makina A.Ş. (“SCS”), an independent compressor distributor located in Adana, Türkiye, has become part of Atlas Copco Group.SCS was founded in 2011 and has 11 employees. The company provides sales and service of air compressor solutions to the Turkish market and is focused on the textile, cement, chemicals, and food & beverage sectors. “With this acquisition we will be able to grow our geographical presence further and serve current and future customers even better”, said Philippe Ernens, Business Area President Compressor Technique. During 2023 the

The subscription period in Crunchfish’s rights issue begins today and the company invites to a webinar about the rights issue

Today, November 6th, 2024, the subscription period in Crunchfish AB’s (“Crunchfish” or the “Company”) rights issue of units of approximately SEK 57 million before issue costs (the “Rights Issue”) begins. The Rights Issue is covered by subscription commitments and guarantee commitments up to approximately 45 percent from larger shareholders and external investors. The Rights Issue was approved at the Extraordinary General Meeting held on October 24, 2024. All interested parties are invited to a webinar about the Rights Issue on November 11th, 2024, where the audience will have the opportunity

Interim report January – September 2024

NET ASSET VALUE AND THE LATOUR SHARE · The net asset value at the end of the period was SEK 216 per share compared with SEK 198 per share at the start of the year, which is an increase of 11.3 per cent adjusted for dividends. The benchmark index (SIXRX) rose 15.2 per cent. The net asset value was SEK 218 per share at 5 November.[1] · The total return on the Latour share was 22.5 per cent measured against the SIXRX, which increased 15.2 per cent. INDUSTRIAL OPERATIONS The third quarter · The industrial operations’ order intake rose 3 per cent to SEK 5,739 m (5,565 m), a 2

ORGANOCLICK AB (PUBL) PUBLISH INTERIM REPORT FOR Q3 2024

"During the third quarter, the trend of good growth continued for our consumer brands, while our industrial products continued to face a challenging market situation. Despite a sales decrease of -14 (50) percent to MSEK 28.9 (33.4) during the quarter, our operating profit/loss was in line with the third quarter of 2023 at MSEK -3.0 (-2.8), thanks to the changed product mix and sound cost control. For the first nine months of the year (Jan–Sept), the operating profit/loss was also in line with the previous year at MSEK -3.0 (-3.1), while cash flow from operating activities was significantly

GomSpace signs 325.000€ contract change notice for Juventas mission

This week, GomSpace and the European Space Agency (ESA) has signed a contract change notice of 325.000€ (3.8MSEK) to support additional project activities.Further strengthening the relationship in the frame of the HERA mission and on the Juventas spacecraft, GomSpace and ESA signed a contract amendment for 325.000€, which will take full effect this year. The amendment aims to support activities adding particular value to the long-term exploitation of the mission as well as during the initial launch phases. “All HERA mission participants have worked hard to get ready for the mission

Two thousand square meters let at Kaserntorget 6

Wallenstam’s initiative involving reuse, green leases and full-service offices ready for occupation at Kaserntorget 6 has been highly sought after. Recently, Prodesign signed an agreement for the last premises of 460 square meters and will move in during January next year. This means that the entire property of about 2,000 square meters in total is now fully let.“Kaserntorget 6 has been an exciting project. Two thousand square meters of office space where we offer our customers a comprehensive solution, which is ready for occupation, featuring wireless connectivity, meeting technology,

Cell Impact Q3 2024: Continued development of the production capacity

Cell Impact has significantly reduced its cost base, and the company is ready for high-volume manufacturing.The Group’s net sales for the third quarter of 2024 amounted to SEK 5.6 million (9.3), down 40 percent year-on-year. - During the quarter, we continued to deliver in our existing partnerships, with a strong focus on our ability to provide highly specialized services that support our customers in developing high-efficiency flow plates that are adapted to our cost-effective production process, said Daniel Vallin, CEO of Cell Impact. Financing deemed sufficient for 2025 The cost-

Ellevio refinances its credit facilities to safeguard the energy transition

Ellevio AB (publ) ("Ellevio") has signed an agreement to refinance its credit facilities totalling SEK 11 billion with a group of 13 banks. The agreement will ensure access to loan financing that will enable Ellevio to continue to carry out the extensive electricity network investments needed to enable electrification and the journey towards fossil-free energy.Ellevio has also increased its credit facilities from SEK 9 billion to SEK 11 billion, which is secured until 2029 with an extension option. The increased credit facilities will enable Ellevio to deliver the anticipated increase in

Metso expands its flotation portfolio with modular Concorde Cell™ Plant Units for accelerated results

Metso Corporation’s press release on November 6, 2024, at 09:00 a.m. EETMetso is expanding its flotation portfolio with modular Concorde Cell™ Plant Units. The new solution consists of prefabricated and pre-installed containerized units, which streamlines the setup process and minimizes on-site installation work. Deployment is safe and rapid, resulting in faster return on investment. “Concorde Cell™ Plant Units feature a complete sampling and automation portfolio, along with a modular basic design that conveniently accommodates add-ins. This flexibility allows for tailored solutions that

ASSA ABLOY acquires Lawrence Doors in the US

ASSA ABLOY has acquired Lawrence Doors, a US manufacturer of coiling steel doors, grilles and counter shutters. "I am very pleased to welcome Lawrence Doors into the ASSA ABLOY Group. This acquisition delivers on our strategy to strengthen our position in mature markets through adding complementary products and solutions to our core business,” says Nico Delvaux, President and CEO of ASSA ABLOY. "With the acquisition of Lawrence Doors, we are set to enter the rapidly growing coiling steel market and establish a strong presence on the US West Coast," says Massimo Grassi, Executive Vice

Relais Group Plc’s share buyback program has ended

Relais Group PlcStock Exchange Release 6 November 2024 at 9:00 a.m. EET On 8 May 2024 the Board of Directors of Relais Group Plc decided to launch a buyback program concerning Relais Group Plc's own shares based on the authorization to repurchase own shares granted by the Annual General Meeting held on 10 April 2024. Relais Group Plc has now completed the share buy-back program. The repurchases of the shares began on 8 May 2024 and ended on 5 November 2024. During that period, Relais Group repurchased 71,735 of its own shares at a total value of EUR 999,971.55. The average purchase

NRC Group ASA – Last day of the Subscription Period in the Subsequent Offering

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Reference is made to the stock exchange notice from NRC Group ASA (the "Company") on 24 October 2024 regarding the commencement of the subscription period (the "Subscription Period") in the subsequent offering (the "Subsequent Offering") consisting of up to 20,000,000

Oneflow’s monthly ARR update: October 2024

Press release8 November 2024 Oneflow publishes its preliminary monthly ARR. Oneflow had a total ARR (Annual Recurring Revenue) of MSEK 160.8 by the end of October 2024. This is a preliminary number. All financial reports and presentations are available for download on our website here: https://oneflow.com/ir/investors/financial-reports/ For further information, please contact: Anders Hamnes, CEO and FounderMobile: +46 76 788 50 76Email: anders.hamnes@oneflow.com Certified Adviser is FNCA Sweden AB. About Oneflow Oneflow develops a contract automation platform

There are no items matching the current filter
There are no more items matching the current filter
Back to top